http://happyandhealthyover40.com/relieving-suffering-emerging-bio-technology/
http://happyandhealthyover40.com/relieving-suffering-emerging-bio-technology/
Tag: immortality – Page 10
Revita Life Sciences Continues to Advance Multi-Modality Protocol in Attempt to Revive Brain Dead Subjects
Posted in bioengineering, biotech/medical, cryonics, futurism, genetics, health, life extension, neuroscience, posthumanism | 2 Comments on Revita Life Sciences Continues to Advance Multi-Modality Protocol in Attempt to Revive Brain Dead Subjects
Rudrapur, Uttrakhand, India — July 02, 2017
Revita Life Sciences, (http://revitalife.co.in) a biotechnology company focused on translational regenerative therapeutic applications, has announced that it is continuing to advance their novel, multi-modality clinical intervention in the state of brain death in humans.
“We have proactively continued to advance our multi-modality protocol, as an extended treatment before extubation, in an attempt to reverse the state of brain death” said Mr.Pranjal Agrawal, CEO Revita Life Sciences. “This treatment approach has yielded some very encouraging initial outcome signs, ranging from minor observations on blood pressure changes with response to painful stimuli, to eye opening and finger movements, with corresponding transient to permanent reversal changes in EEG patterns.”
This first exploratory study, entitled “Non-randomized, Open-labelled, Interventional, Single Group, and Proof of Concept Study with Multi-modality Approach in Cases of Brain Death Due to Traumatic Brain Injury Having Diffuse Axonal Injury” is ongoing at Anupam Hospital, Rudrapur, Uttrakhand. The intervention primarily involves intrathecal administration of minimal manipulated (processed at point of care) autologous stem cells derived from patient’s fat and bone marrow twice a week.
This study was inappropriately removed from the Indian Council of Medical Research (ICMR) database. ICMR has no regulatory oversight on such research in India.
The Central Drugs Standard Control Organization (CDSCO), Drug Controller General of India, had no objection to the program progressing. Regulatory approval as needed for new drugs, is currently not required when research is conducted on the recently deceased, although IRB and family consent is definitely required. CDSCO, the regulator of such studies, clearly states that “no regulatory requirements are needed for any study with minimal manipulated autologous stem cells in brain death subjects”.
Death is defined as the termination of all biological functions that sustain a living organism. Brain death, the complete and irreversible loss of brain function (including involuntary activity necessary to sustain life) as defined in the 1968 report of the Ad Hoc Committee of the Harvard Medical School, is the legal definition of human death in most countries around the world. Either directly through trauma, or indirectly through secondary disease indications, brain death is the final pathological state that over 60 million people globally transfer through each year.
“We are in process of publishing our initial retrospective results, as well ongoing early results, in a peer reviewed journal. These initial findings will prove invaluable to the future evolution of the program, as well as in progressing the development multi-modality regenerative therapeutics for the full range of the severe disorders of consciousness, including coma, PVS, the minimally conscious state, and a range of other degenerative CNS conditions in humans,” said Dr. Himanshu Bansal, Chief Scientific Officer, Revita Life Sciences and Director of Mother Cell.
With the maturation of the tools of medical science in the 21st century, especially cell therapies and regenerative medicines, tissues once considered irretrievable, may finally be able to be revived or rejuvenated. Hence many scientists believe that brain death, as presently defined, may one day be reversed. While the very long term goal is to find a solution for “re-infusing life”, the short term purpose of these types of studies is much less dramatic, which is to confirm if the current definition of brain irreversibility still holds true. There have been many anecdotal reports of brain death reversal across the world over the past decades in the scientific literature. Studies of this nature serve to verify and establish this very fact in a scientific and controlled manner. It will also one day give a fair chance to individuals, who are declared brain dead, especially after trauma.
About Revita Life Sciences
Revita Life Sciences is a biotechnology company focused on the development of stem cell therapies and regenerative medicine interventions that target areas of significant unmet medical need. Revita is led by Dr. Himanshu Bansal MD, who has spent over two decades developing novel MRI based classifications of spinal cord injuries as well as comprehensive treatment protocols with autologous tissues including bone marrow stem cells, Dural nerve grafts, nasal olfactory tissues, and omental transposition.
Philadelphia, PA, USA / Moscow, Russia — Bioquark, Inc., (www.bioquark.com) a life sciences company focused on the development of novel bio-products for regeneration, disease reversion, and healthy aging, and Moscow based, Lakmus LLC, a diversified investment company with business interests in pharmacies, restaurants, and real estate, announced a multi-disciplinary research collaboration with the FSBI Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences (http://www.academpharm.ru/), and the Pavlov Institute of Physiology of the Russian Academy of Sciences (http://www.infran.ru/), to jointly study the pharmacotherapeutic longevity enhancement properties of its combinatorial regenerative biologic candidates.
“We are very excited about this continued collaboration with Lakmus,” said Ira S. Pastor, CEO, Bioquark Inc. “The disciplined development of our combinatorial biologic candidates (Bioquantines) for healthy longevity enhancement, represents another important step in our continued evolution as a company focused on a broad range of therapeutic products and services in the regenerative healthcare space.”
Throughout the 20th century, natural products formed the basis for a majority of all pharmaceuticals, biologics, and consumer healthcare products used by patients around the globe, generating trillions of dollars of wealth. However, many scientists believe we have only touched the surface with what the natural world, and its range of organisms, which from a health and wellness perspective are much further advanced than human beings, has to teach us.
The integration of a complex set of newer research disciplines, including interkingdom signaling, semiochemical communication, and evolutionary biology, as well as significant recent activity in the areas of the microbiome, are highlighting a myriad of new ways that non-human bio-products can affect the human genome for positive transitions in health and wellness dynamics.
“Bioquark has spent several years studying the natural ability of many species to turn back biological time in order to maintain health, fitness, and survival, developing a broad understanding of the combinatorial biochemical approaches they use to control nested hierarchies of disease (i.e. gene, cell, tissue, organism, environment),” said Dr. Sergei Paylian, Founder, CSO, and President, Bioquark Inc. “This research initiative is one more step in the path in allowing humans to recapture these capabilities to effectively counter our unfortunate progression into aging, disease and degeneration.”
About Bioquark, Inc.
Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.
Philadelphia, PA, USA / Moscow, Russia — Bioquark, Inc., (http://www.bioquark.com) a life sciences company focused on the development of novel bio-products for regeneration, disease reversion, and healthy aging, announced the commercial approval of naturally derived Bioquantine food ingredients in the Eurasian Customs Union (formerly known as the Customs Union of Belarus, Kazakhstan, and Russia). Moscow based, Lakmus LLC, a diversified investment company with business interests in pharmacies, restaurants, and real estate, collaborated with Bioquark Inc. on the regulatory approvals.
“We are very excited about this successful regulatory approval,” said Ira S. Pastor, CEO, Bioquark Inc. “The commercialization of Bioquantine food ingredients, including functional foods, drinks, and dietary supplements, represents another important step in our continued evolution as a company focused on a broad range of products and services in the regenerative healthcare space.”
Throughout the 20th century, natural products formed the basis for a majority of all pharmaceuticals, biologics, and consumer healthcare products used by patients around the globe, generating trillions of dollars of wealth. However, many scientists believe we have only touched the surface with what the natural world, and its range of organisms, which from a health and wellness perspective are much further advanced than human beings, has to teach us.
The integration of a complex set of newer research disciplines, including interkingdom signaling, semiochemical communication, and evolutionary biology, as well as significant recent activity in the areas of the microbiome and virome, are highlighting a myriad of new ways that non-human bio-products can affect the human genome for positive transitions in health and wellness dynamics.
“Bioquark has spent several years studying the natural ability of many species to turn back biological time in order to maintain health, fitness, and survival,” said Dr. Sergei Paylian, Founder, CSO, and President, Bioquark Inc. “This Eurasian initiative is one more step in the path in allowing humans to recapture these capabilities to effectively counter our unfortunate progression into aging, disease and degeneration.”
About Bioquark, Inc.
Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.
Link to Press — http://www.prweb.com/releases/2017/01/prweb13955162.htm
Bioquark Inc. (www.bioquark.com) mention on CNBC — the best way to make chemo easier is to eliminate the need for it forever!
Bioquark, Inc., (http://www.bioquark.com) a life sciences company focused on the development of novel, natural bio-products for health, wellness and rejuvenation, has entered a collaboration whereby Forest Organics LLC & I-Beauty Charm LLC, a unique, integrated facial and body cosmetology facility, and their state-licensed, highly skilled skin care specialists, will be utilizing novel, natural Bioquantine™ extract complexes as part of their spa procedures, as well as providing consumer access to a range of proprietary skin care products (http://www.forestorganics.life).
“We are very excited about this first company collaboration in the area of beauty care and cosmetology,” said Ira S. Pastor, CEO, Bioquark Inc. “It is another step forward towards the wide applicability of our natural combinatorial bio-products, across a broad range of health and wellness segments, as well as future franchise opportunities.”
The integrated Forest Organics LLC & I-Beauty Charm LLC model was conceived by local Tampa business women, Nadia Goetzinger and Tatyana Reshetnikova, to offer a new generation of products and services related to skin beautification and rejuvenation.
“We look forward to working closely with Bioquark Inc. on this initiative and providing an exclusive range of services and products to customers throughout the greater Tampa metropolitan area,” said Ms. Goetzinger”
About Bioquark, Inc.
Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biopharmaceutical candidates, as well as non-Rx products for the global consumer health and wellness market segments.
About Forest Organics LLC & I-Beauty Charm LLC
Forest Organics LLC & I-Beauty Charm LLC operate a unique, integrated facial and body cosmetology facility providing novel rejuvenative spa and cosmetology services and products.
Philadelphia, PA, USA / Mexico City, Mexico — Bioquark, Inc., (www.bioquark.com) a life sciences company focused on the development of novel bioproducts for complex regeneration, disease reversion, and aging, and RegenerAge SAPI de CV, (www.regenerage.clinic/en/) a clinical company focused on translational therapeutic applications of a range of regenerative and rejuvenation healthcare interventions, have announced a collaboration to focus on novel combinatorial approaches in human disease and wellness. SGR-Especializada (http://www.sgr-especializada.com/), regulatory experts in the Latin American healthcare market, assisted in the relationship.
“We are very excited about this collaboration with RegenerAge SAPI de CV,” said Ira S. Pastor, CEO, Bioquark Inc. “The natural synergy of our cellular and biologic to applications of regenerative and rejuvenative medicine will make for novel and transformational opportunities in a range of degenerative disorders.”
As we close in on $7 trillion in total annual health care expenditures around the globe ($1 trillion spent on pharmaceutical products; $200 billion on new R&D), we are simultaneously witnessing a paradoxical rise in the prevalence of all chronic degenerative diseases responsible for human suffering and death.
With the emergence of such trends including: personalization of medicine on an “n-of-1” basis, adaptive clinical design, globalization of health care training, compassionate use legislative initiatives for experimental therapies, wider acceptance of complementary medical technologies, and the growth of international medical travel, patients and clinicians are more than ever before, exploring the ability to access the therapies of tomorrow, today.
The estimate of the current market size for procedural medical travel, defined by medical travelers who travel across international borders for the purpose of receiving medical care, is in the range of US $40–55 billion.
Additionally, major clinical trial gaps currently exist across all therapeutic segments that are responsible for human suffering and death. Cancer is one prime example. As a leading cause of morbidity and mortality worldwide for many decades, today there are approximately 14 million new cases diagnosed each year, with over 8 million cancer related deaths annually. It is estimated that less than 5% of these patients, take the initiative to participate in any available clinical studies.
“We look forward to working closely with Bioquark Inc. on this exciting initiative,” said Dr. Joel Osorio, Chief of Clinical Development RegenerAge SAPI de CV. “The ability to merge cellular and biologic approaches represents the next step in achieving comprehensive regeneration and disease reversion events in a range of chronic diseases responsible for human suffering and death.”
About Bioquark, Inc.
Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.
About RegenerAge SAPI de CV
RegenerAge SAPI de CV is a novel clinical company focused on translational therapeutic applications, as well as expedited, experimental access for “no option” patients, to a novel range of regenerative and reparative biomedical products and services, with the goal of reducing human degeneration, suffering, and death.
Fox 29 — Good Day Philadelphia
http://www.fox29.com/140735577-video
NBC TV 10
http://www.nbcphiladelphia.com/news/local/Zombies-from-Phill…65101.html
CNN en Espanol
http://cnnespanol.cnn.com/video/cnnee-encuentro-intvw-joel-o…-cerebral/
Bioquark, Inc., (http://www.bioquark.com) a company focused on the development of novel biologics for complex regeneration and disease reversion, and Revita Life Sciences, (http://revitalife.co.in) a biotechnology company focused on translational therapeutic applications of autologous stem cells, have announced that they have received IRB approval for a study focusing on a novel combinatorial approach to clinical intervention in the state of brain death in humans.
This first trial, within the portfolio of Bioquark’s Reanima Project (http://www.reanima.tech) is entitled “Non-randomized, Open-labeled, Interventional, Single Group, Proof of Concept Study With Multi-modality Approach in Cases of Brain Death Due to Traumatic Brain Injury Having Diffuse Axonal Injury” (https://clinicaltrials.gov/ct2/show/NCT02742857?term=bioquark&rank=1), will enroll an initial 20 subjects, and be conducted at Anupam Hospital in Rudrapur, Uttarakhand India.
“We are very excited about the approval of our protocol,” said Ira S. Pastor, CEO, Bioquark Inc. “With the convergence of the disciplines of regenerative biology, cognitive neuroscience, and clinical resuscitation, we are poised to delve into an area of scientific understanding previously inaccessible with existing technologies.”
Death is defined as the termination of all biological functions that sustain a living organism. Brain death, the complete and irreversible loss of brain function (including involuntary activity necessary to sustain life) as defined in the 1968 report of the Ad Hoc Committee of the Harvard Medical School, is the legal definition of human death in most countries around the world. Either directly through trauma, or indirectly through secondary disease indications, brain death is the final pathological state that over 60 million people globally transfer through each year.
While human beings lack substantial regenerative capabilities in the CNS, many non-human species, such as amphibians, planarians, and certain fish, can repair, regenerate and remodel substantial portions of their brain and brain stem even after critical life-threatening trauma.
Additionally, recent studies on complex brain regeneration in these organisms, have highlighted unique findings in relation to the storage of memories following destruction of the entire brain, which may have wide ranging implications for our understanding of consciousness and the stability of memory persistence.
“Through our study, we will gain unique insights into the state of human brain death, which will have important connections to future therapeutic development for other severe disorders of consciousness, such as coma, and the vegetative and minimally conscious states, as well as a range of degenerative CNS conditions, including Alzheimer’s and Parkinson’s disease,” said Dr. Sergei Paylian, Founder, President, and Chief Science Officer of Bioquark Inc.
Over the years, clinical science has focused heavily on preventing such life and death transitions and made some initial progress with suspended animation technologies, such as therapeutic hypothermia. However, once humans transition through the brain death window, currently defined by the medical establishment as “irreversible”, they are technically no longer alive, despite the fact that human bodies can still circulate blood, digest food, excrete waste, balance hormones, grow, sexually mature, heal wounds, spike a fever, and gestate and deliver a baby. It is even acknowledged by thought leaders that recently brain dead humans still may have residual blood flow and electrical nests of activity in their brains, just not enough to allow for an integrated functioning of the organism as a whole.
“We look forward to working closely with Bioquark Inc. on this cutting edge clinical initiative,” said Dr. Himanshu Bansal, Managing Director of Revita Life Sciences.
About Bioquark, Inc.
Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.
About Revita Life Sciences
Revita Life Sciences is a biotechnology company focused on the development of stem cell therapies that target areas of significant unmet medical need. Revita is led by Dr. Himanshu Bansal MD, PhD. who has spent over two decades developing novel MRI based classifications of spinal cord injuries as well as comprehensive treatment protocols with autologous tissues including bone marrow stem cells, dural nerve grafts, nasal olfactory tissues, and omental transposition.
“He is not here; He has risen,” — Matthew 28:6
As billions of Christians around the world are getting ready to celebrate the Easter festival and holiday, we take pause to appreciate the awe inspiring phenomena of resurrection.
In religious and mythological contexts, in both Western and Eastern societies, well known and less common names appear, such as Attis, Dionysus, Ganesha, Krishna, Lemminkainen, Odin, Osiris, Persephone, Quetzalcoatl, and Tammuz, all of whom were reborn again in the spark of the divine.
In the natural world, other names emerge, which are more ancient and less familiar, but equally fascinating, such as Deinococcus radiodurans, Turritopsis nutricula, and Milnesium tardigradum, all of whose abilities to rise from the ashes of death, or turn back time to start life again, are only beginning to be fully appreciated by the scientific world.
In the current era, from an information technology centric angle, proponents of a technological singularity and transhumanism, are placing bets on artificial intelligence, virtual reality, wearable devices, and other non-biological methods to create a future connecting humans to the digital world.
This Silicon Valley, “electronic resurrection” model has caused extensive deliberation, and various factions to form, from those minds that feel we should slow down and understand the deeper implications of a post-biologic state (Elon Musk, Steven Hawking, Bill Gates, the Vatican), to those that are steaming full speed ahead (Ray Kurzweil / Google) betting that humans will shortly be able to “transcend the limitations of biology”.
However, deferring an in-depth Skynet / Matrix discussion for now, is this debate clouding other possibilities that we have forgotten about, or may not have even yet fully considered?
Today, we find ourselves at an interesting point in history where the disciplines of regenerative sciences, evolutionary medicine, and complex systems biology, are converging to give us an understanding of the cycle of life and death, orders of magnitude more complex than only a few years ago.
In addition to the aforementioned species that are capable of biologic reanimation and turning back time, we show no less respect for those who possess other superhuman capabilities, such as magnetoreception, electrosensing, infrared imaging, and ultrasound detection, all of which nature has been optimizing over hundreds of millions of years, and which provide important clues to the untapped possibilities that currently exist in direct biological interfaces with the physical fabric of the universe.
The biologic information processing occurring in related aneural organisms and multicellular colony aggregators, is no less fascinating, and potentially challenges the notion of the brain as the sole repository of long-term encoded information.
Additionally, studies on memory following the destruction all, or significant parts of the brain, in regenerative organisms such as planarians, amphibians, metamorphic insects, and small hibernating mammals, have wide ranging implications for our understanding of consciousness, as well as to the centuries long debate between the materialists and dualists, as to whether we should focus our attention “in here”, or “out there”.
I am not opposed to studying either path, but I feel that we have the potential to learn a lot more about the topic of “out there” in the very near future.
The study of brain death in human beings, and the application of novel tools for neuro-regeneration and neuro-reanimation, for the first time offer us amazing opportunities to start from a clean slate, and answer questions that have long remained unanswered, as well as uncover a knowledge set previously thought unreachable.
Aside from a myriad of applications towards the range of degenerative CNS indications, as well as disorders of consciousness, such work will allow us to open a new chapter related to many other esoteric topics that have baffled the scientific community for years, and fallen into the realm of obscure curiosities.
From the well documented phenomena of terminal lucidity in end stage Alzheimer’s patients, to the mysteries of induced savant syndrome, to more arcane topics, such as the thousands of cases of children who claim to remember previous lives, by studying death, and subsequently the “biotechnological resurrection” of life, we can for the first time peak through the window, and offer a whole new knowledge base related to our place, and our interaction, with the very structure of reality.
We are entering a very exciting era of discovery and exploration.
About the author
Ira S. Pastor is the Chief Executive Officer of Bioquark Inc. (www.bioquark.com), an innovative life sciences company focusing on developing novel biologic solutions for human regeneration, repair, and rejuvenation. He is also on the board of the Reanima Project (www.reanima.tech)